Elena V. Borodataya

Elena V. Borodataya

Auto-generated profile, based on publicly available information

Elena V. Borodataya

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
SKS. V. Kotov
S. V. Kotov
OSO. P. Sidorova
O. P. Sidorova
EBE. V. Borodataya
E. V. Borodataya
Introduction. With the advent of new drugs — analogues of mitochondrial metabolites, the widespread introduction into practice of research methods for assessing the function of mitochondria in patients with neurological pathology and other diseases becomes relevant.Study aim. To determine the change in the intracellular activity of mitochondrial enzymes (succinate dehydrogenase, α -glycerophosphate dehydrogenase, glutamate dehydrogenase, lactate dehydrogenase) in case of neuromuscular diseases.Materials and methods. We examined 74patients with neuromuscular diseases. The activity of 4 mitochondrial enzymes involved in carbohydrate metabolism (lactate dehydrogenase), amino acid metabolism (glutamate dehydrogenase), fatty acids (α -glycerophosphate dehydrogenase), and mitochondrial respiratory chain complex II (succinate dehydrogenase) was evaluated. For a cytochemical study of the activity of mitochondrial enzymes in peripheral blood lymphocytes, the method proposed by A.G.E. Pearse as modified by R.P. Narcissov.Results. The greatest changes were revealed in cases with myotonic dystrophy: statistically significant decreases in the average activity value of all studied enzymes (р 0.05).In cases with hereditary motor-sensory neuropathy of type I the activity of succinate dehydrogenase and glutamate dehydrogenase is reduced (р 0.05), in cases with type II there are deviations in the activity indicators of mitochondrial enzymes, more pronounced compared with type I, but not statistically significant (p 0.05). In patients with myasthenia gravis, a decrease in the activity of α -glycerophosphate dehydrogenase and glutamate dehydrogenase (p 0.05) was noted. Average values of succinate dehydrogenase and lactate dehydrogenase activity indicators were also reduced (p 0.05). In cases with Landusi-Dejerine myopathy the activity of succinate dehydrogenase, α -glycerophosphate dehydrogenase and glutamate dehydrogenase were reduced, of which only for α -glycerophosphate dehydrogenase p 0.05. In the analysis of each case in groups of patients with the studied pathology, it was shown that in addition to patients with myotonic dystrophy, in which all patients decreased the activity of succinate dehydrogenase, α -glycerophosphate dehydrogenase and glutamate dehydrogenase, in other cases, in some patients, the studied enzyme activity did not change.Conclusion. There are methods for studying these metabolites in plasma. The activity of mitochondrial enzymes is also examined. In cases with neuromuscular diseases, there are violations of the mitochondria. Therefore, it is necessary to consider such patients as metabolic patients and prescribe metabolic, antioxidant therapy to them.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SKS.V. Kotov
S.V. Kotov
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
EBE.V. Borodataya
E.V. Borodataya
To evaluate the efficacy of the energotropic drug idebenon in hereditary neuromuscular pathology. A total of 9 patients with hereditary myopathies were examined during treatment with idebenone. Determination of muscle strength was carried out on the British medical research Council scale (0 points - no active movements, 5 points - no muscle weakness). The examination was performed before and 1 month after the start of treatment. Treatment regimen: idebenone was prescribed in a daily dose of 90 mg. In the general group of patients with hereditary ataxia, the median strength of the biceps muscle of the shoulder during treatment increased from 3.5 to 4.0 points (p>0.05). The median strength of the ilio-lumbar muscle increased from 3.0 to 4.0 points (p>0.05). Before treatment, the median number of sit-ups was 0, and after 1 month - 2 (p>0.05). We used the energotropic drug idebenon, a synthetic analog of the natural substance coenzyme Q10, which is involved in electron transfer in the mitochondrial respiratory chain complex III, for the treatment of patients with hereditary myopathies. In the general group of patients, there was an increase in muscle strength, although it did not reach statistical significance. Before the advent of energotropic drugs, the use of various methods of treating hereditary myopathies did not lead to an increase in muscle strength in patients. Therefore, the identified positive dynamics is of great importance in providing medical care to these patients and improving their quality of life.

1 September 2012 in Cytokine
Verified
Journal Article
Closed access
TOT. Ospelnikova
T. Ospelnikova
VLV.Yu. Lizhdvoy
V.Yu. Lizhdvoy
OSO.P. Sidorova
O.P. Sidorova
SKS.V. Kotov
S.V. Kotov
FYF.I. Yershov
F.I. Yershov

15 January 2022 in Annals of Clinical and Experimental Neurology
Verified
Journal Article
Open access
PDF file
SKSergey V. Kotov
Sergey V. Kotov
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
EBElena V. Borodataya
Elena V. Borodataya
IVIrina A. Vasilenko
Irina A. Vasilenko
ABAlexander V. Borodin
Alexander V. Borodin
Three case studies of adults with Leber hereditary optic neuropathy with and without neurological symptoms are presented. An elevated blood lactate level and changes in the activity of the mitochondrial enzymes in peripheral blood lymphocytes were noted. Mutations in the mitochondrial DNA (G3460A in one patient and G11778A in two patients) were found. The patient with a G3460A mutation, in addition to reduced visual acuity, was diagnosed with a cerebellar disorder due to cerebellar vermis hypoplasia. These changes are indications for prescribing energotropic drugs (idebenone, carnitine); carnosine can also be prescribed. These case studies show that patients with optic nerve atrophy should be assessed for Leber hereditary optic neuropathy. Differential diagnosis with multiple sclerosis should be performed, since this condition often presents as optic neuropathy.

1 January 2021 in Consilium Medicum
Verified
Journal Article
Closed access
OSOlga P. Sidorova
Olga P. Sidorova
SKSergey V. Kotov
Sergey V. Kotov
NDNatalya S. Demikova
Natalya S. Demikova
EBElena V. Borodataya
Elena V. Borodataya
IVIrina A. Vasilenko
Irina A. Vasilenko